User profiles for Alexandra Trkola

Alexandra Trkola

Professor of Medical Virology, University of Zurich
Verified email at virology.uzh.ch
Cited by 18436

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

A Trkola, AB Pomales, H Yuan, B Korber… - Journal of …, 1995 - Am Soc Microbiol
We have tested three human monoclonal antibodies (MAbs) IgG1b12, 2G12, and 2F5) to the
envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1), and a tetrameric …

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5

A Trkola, T Dragic, J Arthos, JM Binley, WC Olson… - Nature, 1996 - nature.com
THE β-chemokine receptor CCR-5 is an essential co-factor for fusion of HIV-1 strains of the
non-syncytium-inducing (NSI) phenotype with CD4 + T-cells 1–5 . The primary binding site …

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

A Trkola, M Purtscher, T Muster, C Ballaun… - Journal of …, 1996 - Am Soc Microbiol
We have isolated and characterized human monoclonal antibody 2G12 to the gp120 surface
glycoprotein of human immunodeficiency virus type 1 (HIV-1). This antibody potently and …

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

T Dragic, A Trkola, DAD Thompson… - Proceedings of the …, 2000 - National Acad Sciences
HIV-1 entry into CD4 + cells requires the sequential interactions of the viral envelope
glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCR5 and CXCR4. A …

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

A Trkola, H Kuster, P Rusert, B Joos, M Fischer… - Nature medicine, 2005 - nature.com
To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …

Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2

…, S Fernbach, MO Pohl, U Karakus, M Huber, A Trkola… - MBio, 2020 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), is a recently emerged respiratory coronavirus that has infected >…

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

A Trkola, SE Kuhmann, JM Strizki… - Proceedings of the …, 2002 - National Acad Sciences
To study HIV-1 escape from a coreceptor antagonist, the R5 primary isolate CC1/85 was
passaged in peripheral blood mononuclear cells with increasing concentrations of the CCR5-…

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

T Muster, F Steindl, M Purtscher, A Trkola… - Journal of …, 1993 - Am Soc Microbiol
Vaccination against human immunodeficiency virus type 1 (HIV-1) requires an immunogen
which will elicit a protective immunity against viruses that show a high degree of genetic …

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

A Trkola, TJ Ketas, KA Nagashima, L Zhao… - Journal of …, 2001 - Am Soc Microbiol
CCR5 serves as a requisite fusion coreceptor for clinically relevant strains of human
immunodeficiency virus type 1 (HIV-1) and provides a promising target for antiviral therapy. However…

[HTML][HTML] Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies

…, L Reynell, HF Günthard, P Rusert, A Trkola - PLoS …, 2012 - journals.plos.org
HIV is known to spread efficiently both in a cell-free state and from cell to cell, however the
relative importance of the cell-cell transmission mode in natural infection has not yet been …